Kidney Cancer Clinical Trial

Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study

Summary

This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where it first started (primary site) to a limited (2-5) number of places in the body (metastatic). Study doctors want to find out if this approach is better or worse than the usual approach for metastatic kidney cancer. The usual approach is defined as the care most people get for metastatic kidney cancer which includes systemic therapy such as immunotherapy (given through the veins) and/or small molecular inhibitor (tablets taken by mouth). Radiotherapy uses high energy x-rays to kill cancer cells and shrink tumors. SAbR uses special equipment to position a patient and deliver radiation to tumors with high precision. Giving SAbR prior to systemic therapy may kill more tumor cells than the usual approach, which is systemic therapy alone.

View Full Description

Full Description

PRIMARY OBJECTIVES:

I. To compare overall survival (OS) between patients receiving SAbR + systemic therapy (SABR+ST) versus systemic therapy (ST) only.

II. To compare average adverse event (AE) score between SAbR+ST arm and ST only arm.

SECONDARY OBJECTIVES:

I. To compare global health status / quality of life (QOL) between patients receiving SAbR+ST versus ST only.

II. To compare progression-free survival (PFS) between the arms.

EXPLORATORY OBJECTIVES:

I. To estimate PFS on first line systemic therapy (PFS-SST) in the SAbR+ST arm and compare with first line systemic therapy PFS of the ST arm.

II. To explore local control from SAbR by looking at the amount of local failures after SAbR in the SAbR+ST arm.

III. To assess the cost-effectiveness between the arms in terms of cost per unit gain in quality-of-life years.

QOL OBJECTIVES:

I. To compare global health status / quality of life (QOL) between patients receiving SabR+ST versus ST only using the National Comprehensive Cancer Network (NCCN) / Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index -19 item (NFKSI-19).

II. To compare quality-adjusted survival between patients randomized to receive SabR+ST vs ST alone using European Quality of Life (EUROQOL) 5-dimension, 5-level (EQ-5D-5L) at 3, 6, 9, 12, 18, and 24 months.

III. To compare global health status / QOL of the NFKSI-19 at all of the 3, 6, 9, 12, 18, and 24 month time points between patients randomized to receive SabR+ST versus ST alone.

IV. To compare scale scores of the NFKSI-19 (disease-related symptoms - physical disease-related symptoms - emotional, treatment side effects, and function & well-being) at 3, 6, 9, 12, 18, 24 months between patients randomized to receive SabR+ST versus ST alone.

V. To compare time to global quality of life deterioration between patients randomized to receive SabR+ST versus ST alone using NFKSI-19.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive standard of care systemic therapy on study.

ARM II: Patients undergo repeated SAbR until progression and then receive standard of care systemic therapy on study.

Patients in both arms undergo computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient must be >= 18 years of age
Patient must have a pathologically (histologically or cytologically) proven diagnosis of renal cell carcinoma (RCC) prior to randomization
Patient may have any RCC histology except a histology that has a sarcomatoid component
Patient must have primary site addressed by local therapy. If the primary RCC is intact, the patient must undergo local treatment to the primary before randomization
Patient must have favorable or intermediate International Metastatic RCC Database Consortium (IMDC) risk (0-2) at the time of randomization
Patient must have a total of between 2 and 5 metastatic lesions, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria with imaging obtained within 45 days prior to randomization
Patient must have a documentation from a radiation oncologist confirming that all sites are amenable to SAbR
Patient may have received prior therapy in the adjuvant setting as long as potential trial participants have recovered from clinically significant adverse events of their most recent therapy/intervention prior to enrollment
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better

All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy

A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:

Has achieved menarche at some point
Has not undergone a hysterectomy or bilateral oophorectomy
Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
Patient must have a Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
Patients must have adequate organ and bone marrow function as per the recommended guidelines and the respective Food and Drug Administration [FDA] package insert required for the systemic therapy chosen by the treating oncologist. We recognize that patients may have varying levels of renal and liver function that will impact which systemic therapy is appropriate for the patient. We do not require all patients to have specific baseline laboratory thresholds but do ask the treating oncologist to attest that the patient has adequate organ and bone marrow function to safely receive one of the first line systemic therapies listed in the protocol as a standard of care treatment option
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial. Testing for HIV is not required for entry onto the study
For patients with history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. If no previous history, testing for HBV is not required for entry onto the study
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. If no previous history, testing for HCV is not required for entry onto the study

In order to participate in the QOL portion of the protocol, the patient must speak one of the languages in which the NFKSI-19 and EQ-5D-5L is available

NOTE: Sites cannot translate the associated QOL forms

Exclusion Criteria:

Patient must not have brain metastases
Patient must not have metastasis involving the following locations: ultra-central (within 2cm of carina) lung, invading gastrointestinal tract (such as esophagus, stomach, intestines, colon, rectum), skin, and scalp
Patient must not have received any prior systemic therapy (except for adjuvant setting) for metastatic RCC
Active autoimmune disease requiring ongoing therapy including systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications daily. Inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies
Active tuberculosis (purified protein derivative [PPD] response without active TB is allowed)
Uncontrolled hypertension (systolic blood pressure [BP] > 190mmHg or diastolic BP > 110mmHg)
Major surgery within 30 days prior to randomization
Any serious (requiring hospital stay or long term rehab) non-healing wound, ulcer, or bone fracture within 30 days prior to randomization
Any arterial thrombotic (ST elevation myocardial infarction [STEMI], non-STEMI [NSTEMI], cerebrovascular accident [CVA], etc.) events within 180 days prior to randomization
Moderate or severe hepatic impairment (child-Pugh B or C)
Untreated pulmonary embolism (PE) or deep-vein thrombosis (DVT) is not allowed. Treated PE or DVT is allowed > 30 days from diagnosis and when not resulting in respiratory impairment
Unstable cardiac arrhythmia within 180 days prior to randomization
History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, bowel obstruction, or gastric outlet obstruction within 180 days prior to randomization
History of or active inflammatory bowel disease
Malabsorption syndrome within 30 days prior to randomization
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used
Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 6 months after the last dose of protocol treatment

Study is for people with:

Kidney Cancer

Phase:

Phase 3

Estimated Enrollment:

472

Study ID:

NCT05863351

Recruitment Status:

Recruiting

Sponsor:

ECOG-ACRIN Cancer Research Group

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 86 Locations for this study

See Locations Near You

University of Alabama at Birmingham Cancer Center
Birmingham Alabama, 35233, United States
UCHealth University of Colorado Hospital
Aurora Colorado, 80045, United States More Info
Site Public Contact
Contact
720-848-0650
Tyler Robin
Principal Investigator
Poudre Valley Hospital
Fort Collins Colorado, 80524, United States More Info
Site Public Contact
Contact
970-297-6150
Tyler Robin
Principal Investigator
Cancer Care and Hematology-Fort Collins
Fort Collins Colorado, 80528, United States More Info
Site Public Contact
Contact
[email protected]
Tyler Robin
Principal Investigator
UCHealth Greeley Hospital
Greeley Colorado, 80631, United States More Info
Site Public Contact
Contact
[email protected]
Tyler Robin
Principal Investigator
UCHealth Highlands Ranch Hospital
Highlands Ranch Colorado, 80129, United States More Info
Site Public Contact
Contact
720-848-0650
Tyler Robin
Principal Investigator
Medical Center of the Rockies
Loveland Colorado, 80538, United States More Info
Site Public Contact
Contact
970-203-7083
Tyler Robin
Principal Investigator
Saint Joseph Medical Center
Bloomington Illinois, 61701, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Bloomington
Bloomington Illinois, 61704, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Canton
Canton Illinois, 61520, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Carthage
Carthage Illinois, 62321, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Centralia Oncology Clinic
Centralia Illinois, 62801, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Northwestern University
Chicago Illinois, 60611, United States More Info
Site Public Contact
Contact
312-695-1301
[email protected]
Sean Sachdev
Principal Investigator
University of Illinois
Chicago Illinois, 60612, United States More Info
Site Public Contact
Contact
312-355-3046
Matthew Koshy
Principal Investigator
Carle at The Riverfront
Danville Illinois, 61832, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Daniel H. Barnett
Principal Investigator
Cancer Care Specialists of Illinois - Decatur
Decatur Illinois, 62526, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Decatur Memorial Hospital
Decatur Illinois, 62526, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Northwestern Medicine Cancer Center Kishwaukee
DeKalb Illinois, 60115, United States More Info
Site Public Contact
Contact
630-352-5360
[email protected]
Sean Sachdev
Principal Investigator
Carle Physician Group-Effingham
Effingham Illinois, 62401, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Daniel H. Barnett
Principal Investigator
Crossroads Cancer Center
Effingham Illinois, 62401, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Eureka
Eureka Illinois, 61530, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Galesburg
Galesburg Illinois, 61401, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Northwestern Medicine Cancer Center Delnor
Geneva Illinois, 60134, United States More Info
Site Public Contact
Contact
630-352-5360
[email protected]
Sean Sachdev
Principal Investigator
Illinois CancerCare-Kewanee Clinic
Kewanee Illinois, 61443, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Macomb
Macomb Illinois, 61455, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Carle Physician Group-Mattoon/Charleston
Mattoon Illinois, 61938, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Daniel H. Barnett
Principal Investigator
Cancer Care Center of O'Fallon
O'Fallon Illinois, 62269, United States
Illinois CancerCare-Ottawa Clinic
Ottawa Illinois, 61350, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Pekin
Pekin Illinois, 61554, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Peoria
Peoria Illinois, 61615, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
Peoria Illinois, 61615, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
OSF Saint Francis Medical Center
Peoria Illinois, 61637, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Peru
Peru Illinois, 61354, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Princeton
Princeton Illinois, 61356, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Southern Illinois University School of Medicine
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
217-545-7929
Bryan A. Faller
Principal Investigator
Springfield Clinic
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
800-444-7541
Bryan A. Faller
Principal Investigator
Memorial Medical Center
Springfield Illinois, 62781, United States More Info
Site Public Contact
Contact
217-528-7541
[email protected]
Bryan A. Faller
Principal Investigator
Carle Cancer Center
Urbana Illinois, 61801, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Daniel H. Barnett
Principal Investigator
Northwestern Medicine Cancer Center Warrenville
Warrenville Illinois, 60555, United States More Info
Site Public Contact
Contact
630-352-5360
[email protected]
Sean Sachdev
Principal Investigator
Illinois CancerCare - Washington
Washington Illinois, 61571, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Mary Greeley Medical Center
Ames Iowa, 50010, United States More Info
Site Public Contact
Contact
515-956-4132
Joseph J. Merchant
Principal Investigator
McFarland Clinic - Ames
Ames Iowa, 50010, United States More Info
Site Public Contact
Contact
515-239-4734
[email protected]
Joseph J. Merchant
Principal Investigator
Mission Cancer and Blood - Ankeny
Ankeny Iowa, 50023, United States More Info
Site Public Contact
Contact
515-282-2921
Joshua Lukenbill
Principal Investigator
Mercy Hospital
Cedar Rapids Iowa, 52403, United States More Info
Site Public Contact
Contact
319-365-4673
Deborah W. Wilbur
Principal Investigator
Oncology Associates at Mercy Medical Center
Cedar Rapids Iowa, 52403, United States More Info
Site Public Contact
Contact
319-363-2690
Deborah W. Wilbur
Principal Investigator
Medical Oncology and Hematology Associates-West Des Moines
Clive Iowa, 50325, United States More Info
Site Public Contact
Contact
515-241-3305
Richard L. Deming
Principal Investigator
Iowa Methodist Medical Center
Des Moines Iowa, 50309, United States More Info
Site Public Contact
Contact
515-241-6727
Joshua Lukenbill
Principal Investigator
Medical Oncology and Hematology Associates-Des Moines
Des Moines Iowa, 50309, United States More Info
Site Public Contact
Contact
515-241-3305
Joshua Lukenbill
Principal Investigator
Mission Cancer and Blood - Laurel
Des Moines Iowa, 50314, United States More Info
Site Public Contact
Contact
515-241-3305
Richard L. Deming
Principal Investigator
University of Kansas Clinical Research Center
Fairway Kansas, 66205, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Elizabeth M. Wulff-Burchfield
Principal Investigator
University of Kansas Cancer Center
Kansas City Kansas, 66160, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Elizabeth M. Wulff-Burchfield
Principal Investigator
Olathe Health Cancer Center
Olathe Kansas, 66061, United States More Info
Site Public Contact
Contact
913-355-8000
[email protected]
Elizabeth M. Wulff-Burchfield
Principal Investigator
University of Kansas Cancer Center-Overland Park
Overland Park Kansas, 66210, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Elizabeth M. Wulff-Burchfield
Principal Investigator
University of Kansas Hospital-Indian Creek Campus
Overland Park Kansas, 66211, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Elizabeth M. Wulff-Burchfield
Principal Investigator
Salina Regional Health Center
Salina Kansas, 67401, United States More Info
Site Public Contact
Contact
785-452-7038
[email protected]
Elizabeth M. Wulff-Burchfield
Principal Investigator
University of Kansas Health System Saint Francis Campus
Topeka Kansas, 66606, United States More Info
Site Public Contact
Contact
785-295-8000
Elizabeth M. Wulff-Burchfield
Principal Investigator
University of Kansas Hospital-Westwood Cancer Center
Westwood Kansas, 66205, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Elizabeth M. Wulff-Burchfield
Principal Investigator
The James Graham Brown Cancer Center at University of Louisville
Louisville Kentucky, 40202, United States More Info
Site Public Contact
Contact
502-562-3429
Scott R. Silva
Principal Investigator
Saint Joseph Mercy Hospital
Ann Arbor Michigan, 48106, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Samir Narayan
Principal Investigator
Saint Joseph Mercy Brighton
Brighton Michigan, 48114, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Samir Narayan
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton Michigan, 48114, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Samir Narayan
Principal Investigator
Saint Joseph Mercy Canton
Canton Michigan, 48188, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Samir Narayan
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton Michigan, 48188, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Samir Narayan
Principal Investigator
Saint Joseph Mercy Chelsea
Chelsea Michigan, 48118, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Samir Narayan
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea Michigan, 48118, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Samir Narayan
Principal Investigator
University of Michigan Health - Sparrow Lansing
Lansing Michigan, 48912, United States More Info
Site Public Contact
Contact
517-364-3712
[email protected]
Samir Narayan
Principal Investigator
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia Michigan, 48154, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Samir Narayan
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti Michigan, 48197, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Samir Narayan
Principal Investigator
Saint Francis Medical Center
Cape Girardeau Missouri, 63703, United States More Info
Site Public Contact
Contact
573-334-2230
[email protected]
Bryan A. Faller
Principal Investigator
University of Kansas Cancer Center - North
Kansas City Missouri, 64154, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Elizabeth M. Wulff-Burchfield
Principal Investigator
University of Kansas Cancer Center - Lee's Summit
Lee's Summit Missouri, 64064, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Elizabeth M. Wulff-Burchfield
Principal Investigator
University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City Missouri, 64116, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Elizabeth M. Wulff-Burchfield
Principal Investigator
Mercy Hospital South
Saint Louis Missouri, 63128, United States More Info
Site Public Contact
Contact
314-525-6042
[email protected]
Jay W. Carlson
Principal Investigator
Mercy Hospital Saint Louis
Saint Louis Missouri, 63141, United States More Info
Site Public Contact
Contact
314-251-7066
Jay W. Carlson
Principal Investigator
Mercy Hospital Springfield
Springfield Missouri, 65804, United States More Info
Site Public Contact
Contact
417-269-4520
Jay W. Carlson
Principal Investigator
Northwell Health/Center for Advanced Medicine
Lake Success New York, 11042, United States More Info
Site Public Contact
Contact
516-734-8896
Louis Potters
Principal Investigator
Lenox Hill Hospital
New York New York, 10021, United States More Info
Site Public Contact
Contact
516-734-8896
Louis Potters
Principal Investigator
Manhattan Eye Ear and Throat Hospital
New York New York, 10065, United States More Info
Site Public Contact
Contact
212-434-4460
Louis Potters
Principal Investigator
Sanford Bismarck Medical Center
Bismarck North Dakota, 58501, United States More Info
Site Public Contact
Contact
701-323-5760
[email protected]
Daniel Almquist
Principal Investigator
Sanford Broadway Medical Center
Fargo North Dakota, 58122, United States More Info
Site Public Contact
Contact
701-323-5760
[email protected]
Daniel Almquist
Principal Investigator
Sanford Roger Maris Cancer Center
Fargo North Dakota, 58122, United States More Info
Site Public Contact
Contact
701-234-6161
[email protected]
Daniel Almquist
Principal Investigator
University of Oklahoma Health Sciences Center
Oklahoma City Oklahoma, 73104, United States More Info
Site Public Contact
Contact
405-271-8777
[email protected]
Tyler Gunter
Principal Investigator
ECOG-ACRIN Cancer Research Group
Philadelphia Pennsylvania, 19103, United States More Info
Raquibul Hannan
Contact
[email protected]
Raquibul Hannan
Principal Investigator
Sanford Cancer Center Oncology Clinic
Sioux Falls South Dakota, 57104, United States More Info
Site Public Contact
Contact
605-312-3320
[email protected]
Daniel Almquist
Principal Investigator
Sanford USD Medical Center - Sioux Falls
Sioux Falls South Dakota, 57117, United States More Info
Site Public Contact
Contact
605-312-3320
[email protected]
Daniel Almquist
Principal Investigator
UT Southwestern Simmons Cancer Center - RedBird
Dallas Texas, 75237, United States More Info
Site Public Contact
Contact
214-648-7097
[email protected]
Qian Qin
Principal Investigator
UT Southwestern/Simmons Cancer Center-Dallas
Dallas Texas, 75390, United States More Info
Site Public Contact
Contact
214-648-7097
[email protected]
Qian Qin
Principal Investigator
UT Southwestern/Simmons Cancer Center-Fort Worth
Fort Worth Texas, 76104, United States More Info
Site Public Contact
Contact
214-648-7097
[email protected]
Qian Qin
Principal Investigator
UT Southwestern Clinical Center at Richardson/Plano
Richardson Texas, 75080, United States More Info
Site Public Contact
Contact
972-669-7044
[email protected]
Qian Qin
Principal Investigator
VCU Massey Cancer Center at Stony Point
Richmond Virginia, 23235, United States More Info
Site Public Contact
Contact
[email protected]
John Melson
Principal Investigator
Virginia Commonwealth University/Massey Cancer Center
Richmond Virginia, 23298, United States More Info
Site Public Contact
Contact
[email protected]
John Melson
Principal Investigator
Marshfield Medical Center-EC Cancer Center
Eau Claire Wisconsin, 54701, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Anderson A. Bauer
Principal Investigator
University of Wisconsin Carbone Cancer Center
Madison Wisconsin, 53792, United States More Info
Site Public Contact
Contact
800-622-8922
[email protected]
Christos Kyriakopoulos
Principal Investigator
Marshfield Medical Center-Marshfield
Marshfield Wisconsin, 54449, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Anderson A. Bauer
Principal Investigator
Marshfield Clinic-Minocqua Center
Minocqua Wisconsin, 54548, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Anderson A. Bauer
Principal Investigator
Marshfield Medical Center-Rice Lake
Rice Lake Wisconsin, 54868, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Anderson A. Bauer
Principal Investigator
Marshfield Medical Center-River Region at Stevens Point
Stevens Point Wisconsin, 54482, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Anderson A. Bauer
Principal Investigator
Marshfield Medical Center - Weston
Weston Wisconsin, 54476, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Anderson A. Bauer
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Phase 3

Estimated Enrollment:

472

Study ID:

NCT05863351

Recruitment Status:

Recruiting

Sponsor:


ECOG-ACRIN Cancer Research Group

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider